

Special Issue

Advances in Circulating Tumor Cells as a Liquid Biopsy for Cancers

Message from the Guest Editors

Cancer-related deaths have been attributed to the metastatic spread of tumour cells from the primary lesion to distant organs. As dissemination mostly occurs through the blood, the detection and characterisation of circulating tumour cells (CTCs) have become promising areas of oncology research. In the last decade, studies on CTCs have provided important insights into their role in cancer dissemination and, as one of the pillars constituting “liquid biopsy”, their potential utility as a clinically useful biomarker for timely disease detection, treatment response and disease progression evaluation, elucidation of disease mechanisms, and therapeutic target identification for drug development. This Special Issue invites experts to contribute original research articles, as well as review articles, that describe the recent advances in CTC research in various cancer types.

Guest Editors

Dr. Leslie Calapre

Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Perth, Australia

Dr. Aaron Beasley

Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Perth, Australia

Deadline for manuscript submissions

closed (29 February 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/161724

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)